prikaz prve stranice dokumenta Tumor necrosis factor antagonists in the treatment of pyoderma gangrenosum, acne and suppurative hidradenitis (PASH) syndrome
  Preuzmi
PDF 184.26 KB
Znanstveni rad - Prikaz slučaja
Tumor necrosis factor antagonists in the treatment of pyoderma gangrenosum, acne and suppurative hidradenitis (PASH) syndrome
Acta Dermatovenerologica Croatica, 26 (2018), 2; 173-178. urn:nbn:hr:184:217748
Saint-Georges, Valentina; Peternel, Sandra; Kaštelan, Marija; Brajac, Ines

Institucijski repozitorij: Repozitorij Medicinskog fakulteta u Rijeci

Citirajte ovaj rad

Saint Georges, V., Peternel, S., Kaštelan, M. i Brajac, I. (2018). Tumor necrosis factor antagonists in the treatment of pyoderma gangrenosum, acne and suppurative hidradenitis (PASH) syndrome. Acta Dermatovenerologica Croatica, 26. (2), 173-178. Preuzeto s https://urn.nsk.hr/urn:nbn:hr:184:217748

Saint Georges, Valentina, et al. "Tumor necrosis factor antagonists in the treatment of pyoderma gangrenosum, acne and suppurative hidradenitis (PASH) syndrome." Acta Dermatovenerologica Croatica, vol. 26, br. 2, 2018, str. 173-178. https://urn.nsk.hr/urn:nbn:hr:184:217748

Saint Georges, Valentina, Sandra Peternel, Marija Kaštelan i Ines Brajac. "Tumor necrosis factor antagonists in the treatment of pyoderma gangrenosum, acne and suppurative hidradenitis (PASH) syndrome." Acta Dermatovenerologica Croatica 26, br. 2 (2018): 173-178. https://urn.nsk.hr/urn:nbn:hr:184:217748

Saint Georges, V., et al. (2018) 'Tumor necrosis factor antagonists in the treatment of pyoderma gangrenosum, acne and suppurative hidradenitis (PASH) syndrome', Acta Dermatovenerologica Croatica, 26(2), str. 173-178. Preuzeto s: https://urn.nsk.hr/urn:nbn:hr:184:217748 (Datum pristupa: 18.05.2024.)

Saint Georges V, Peternel S, Kaštelan M, Brajac I. Tumor necrosis factor antagonists in the treatment of pyoderma gangrenosum, acne and suppurative hidradenitis (PASH) syndrome. Acta Dermatovenerologica Croatica [Internet]. 2018. [pristupljeno 18.05.2024.];26(2):173-178. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:184:217748

V. Saint Georges, S. Peternel, M. Kaštelan i I. Brajac, "Tumor necrosis factor antagonists in the treatment of pyoderma gangrenosum, acne and suppurative hidradenitis (PASH) syndrome", Acta Dermatovenerologica Croatica, vol. 26, br. 2, str. 173-178, 2018. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:184:217748. [Citirano: 18.05.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:184:217748
Podaci o radu
Naslov (engleski)Tumor necrosis factor antagonists in the treatment of pyoderma gangrenosum, acne and suppurative hidradenitis (PASH) syndrome
AutorValentina Saint-Georges
AutorSandra Peternel
AutorMarija Kaštelan
AutorInes Brajac
Autorova ustanovaSveučilište u Rijeci
Medicinski fakultet
(Katedra za dermatovenerologiju)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Dermatovenerologija
Sažetak (engleski)
The clinical triad of pyoderma gangrenosum (PG), acne and suppurative hidradenitis (HS) has been described under the acronym PASH syndrome and is considered to represent a distinct entity in the group of autoinflammatory diseases. It is a fairly new, only recently recognized disorder with a limited number of reported cases and without defined treatment recommendations. We aimed to summarize currently available data on the use of tumor necrosis factor (TNF) antagonists in the management of PASH syndrome and report on our own experience with the use of adalimumab in a patient presenting with this specific constellation of clinical signs and symptoms. Among the 11 cases identified in the literature, infliximab and adalimumab were the most commonly used agents, both exhibiting favorable effects in the majority of, but not all, patients. This was particularly evident in terms of relatively rapid remission of PG whereas HS lesions seemed to be more resistant to treatment. In our patient, adalimumab monotherapy resulted in a remarkable and sustained remission, although significant improvement of HS lesions was observed only from week 16 of therapy onwards. In summary, TNF antagonists are a promising treatment for PASH ; however, conclusions regarding the choice of a specific agent, optimal dosing or use in combination with other treatment modalities cannot yet be drawn.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Prikaz slučaja
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaActa Dermatovenerologica Croatica
Brojčani podacivol. 26, br. 2, str. 173-178
p-ISSN1330-027X
e-ISSN1847-6538
URN:NBNurn:nbn:hr:184:217748
Datum objave publikacije2018
URL dokumentahttp://bib.irb.hr/888271
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje-Nekomercijalno-Bez prerada 4.0 međunarodna (CC BY-NC-ND 4.0)
Datum i vrijeme pohrane2022-03-14 11:39:04